<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;ff=20240222011100&amp;v=2.18.0.post9+e462414
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;ff=20240222011100&amp;v=2.18.0.post9+e462414" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Thu, 22 Feb 2024 06:11:00 +0000</lastbuilddate>
<pubDate>Wed, 21 Feb 2024 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>Professional Liability: The Problem That Will Not Go Away</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38383102/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240222011100&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Feb 27;83(8):869-872. doi: 10.1016/j.jacc.2024.01.008.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38383102/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240222011100&v=2.18.0.post9+e462414">38383102</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.01.008>10.1016/j.jacc.2024.01.008</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38383102</guid>
<pubDate>Wed, 21 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Richard A Chazal</dc:creator>
<dc:creator>Fred M Kusumoto</dc:creator>
<dc:creator>B Hadley Wilson</dc:creator>
<dc:creator>Richard E Anderson</dc:creator>
<dc:date>2024-02-21</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Professional Liability: The Problem That Will Not Go Away</dc:title>
<dc:identifier>pmid:38383102</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.01.008</dc:identifier>
</item>
<item>
<title>Sports Participation by Athletes With Cardiovascular Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38383101/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240222011100&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Feb 27;83(8):865-868. doi: 10.1016/j.jacc.2023.12.021.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38383101/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240222011100&v=2.18.0.post9+e462414">38383101</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.12.021>10.1016/j.jacc.2023.12.021</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38383101</guid>
<pubDate>Wed, 21 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Matthew W Martinez</dc:creator>
<dc:creator>Michael J Ackerman</dc:creator>
<dc:creator>George J Annas</dc:creator>
<dc:creator>Aaron L Baggish</dc:creator>
<dc:creator>Sharlene M Day</dc:creator>
<dc:creator>Kimberly G Harmon</dc:creator>
<dc:creator>Jonathan H Kim</dc:creator>
<dc:creator>Benjamin D Levine</dc:creator>
<dc:creator>Margot Putukian</dc:creator>
<dc:creator>Rachel Lampert</dc:creator>
<dc:date>2024-02-21</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Sports Participation by Athletes With Cardiovascular Disease</dc:title>
<dc:identifier>pmid:38383101</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.12.021</dc:identifier>
</item>
<item>
<title>"Food Is Medicine" Strategies for Nutrition Security and Cardiometabolic Health Equity: JACC State-of-the-Art Review</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38383100/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240222011100&amp;v=2.18.0.post9+e462414
      <description>"Food Is Medicine" (FIM) represents a spectrum of food-based interventions integrated into health care for patients with specific health conditions and often social needs. Programs include medically tailored meals, groceries, and produce prescriptions, with varying levels of nutrition and culinary education. Supportive advances include expanded care pathways and payment models, e-screening for food and nutrition security, and curricular and accreditation requirements for medical nutrition...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Feb 27;83(8):843-864. doi: 10.1016/j.jacc.2023.12.023.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">"Food Is Medicine" (FIM) represents a spectrum of food-based interventions integrated into health care for patients with specific health conditions and often social needs. Programs include medically tailored meals, groceries, and produce prescriptions, with varying levels of nutrition and culinary education. Supportive advances include expanded care pathways and payment models, e-screening for food and nutrition security, and curricular and accreditation requirements for medical nutrition education. Evidence supports positive effects of FIM on food insecurity, diet quality, glucose control, hypertension, body weight, disease self-management, self-perceived physical and mental health, and cost-effectiveness or cost savings. However, most studies to date are quasiexperimental or pre/post interventions; larger randomized trials are ongoing. New national and local programs and policies are rapidly accelerating FIM within health care. Remaining research gaps require rigorous, iterative evaluation. Successful incorporation of FIM into health care will require multiparty partnerships to assess, optimize, and scale these promising treatments to advance health and health equity.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38383100/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240222011100&v=2.18.0.post9+e462414">38383100</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.12.023>10.1016/j.jacc.2023.12.023</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38383100</guid>
<pubDate>Wed, 21 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Dariush Mozaffarian</dc:creator>
<dc:creator>Karen E Aspry</dc:creator>
<dc:creator>Kathryn Garfield</dc:creator>
<dc:creator>Penny Kris-Etherton</dc:creator>
<dc:creator>Hilary Seligman</dc:creator>
<dc:creator>Gladys P Velarde</dc:creator>
<dc:creator>Kim Williams</dc:creator>
<dc:creator>Eugene Yang</dc:creator>
<dc:creator>ACC Prevention of Cardiovascular Disease Section Nutrition and Lifestyle Working Group and Disparities of Care Working Group</dc:creator>
<dc:date>2024-02-21</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>"Food Is Medicine" Strategies for Nutrition Security and Cardiometabolic Health Equity: JACC State-of-the-Art Review</dc:title>
<dc:identifier>pmid:38383100</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.12.023</dc:identifier>
</item>
<item>
<title>Cardiac Care of Childhood Cancer Survivors: Time to Act Instead of React</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38383099/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240222011100&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Feb 27;83(8):839-842. doi: 10.1016/j.jacc.2023.12.018.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38383099/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240222011100&v=2.18.0.post9+e462414">38383099</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.12.018>10.1016/j.jacc.2023.12.018</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38383099</guid>
<pubDate>Wed, 21 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Lavanya Kondapalli</dc:creator>
<dc:creator>Linda Overholser</dc:creator>
<dc:creator>Carrie Lenneman</dc:creator>
<dc:date>2024-02-21</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Cardiac Care of Childhood Cancer Survivors: Time to Act Instead of React</dc:title>
<dc:identifier>pmid:38383099</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.12.018</dc:identifier>
</item>
<item>
<title>Mortality After Major Cardiovascular Events in Survivors of Childhood Cancer</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38383098/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240222011100&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Survivors of childhood cancer represent a population at high risk for mortality after major cardiovascular events.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Feb 27;83(8):827-838. doi: 10.1016/j.jacc.2023.12.022.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Adult survivors of childhood cancer are at risk for cardiovascular events.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: In this study, we sought to determine the risk for mortality after a major cardiovascular event among childhood cancer survivors compared with noncancer populations.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: All-cause and cardiovascular cause-specific mortality risks after heart failure (HF), coronary artery disease (CAD), or stroke were compared among survivors and siblings in the Childhood Cancer Survivor Study (CCSS) and participants in the Coronary Artery Risk Development in Young Adults (CARDIA) study. Cox proportional hazard regression models were used to estimate HRs and 95% CIs between groups, adjusted for demographic and clinical factors.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 25,658 childhood cancer survivors (median age at diagnosis 7 years, median age at follow-up or death 38 years) and 5,051 siblings, 1,780 survivors and 91 siblings had a cardiovascular event. After HF, CAD, and stroke, 10-year all-cause mortalities were 30% (95% CI: 26%-33%), 36% (95% CI: 31%-40%), and 29% (95% CI: 24%-33%), respectively, among survivors vs 14% (95% CI: 0%-25%), 14% (95% CI: 2%-25%), and 4% (95% CI: 0%-11%) among siblings. All-cause mortality risks among childhood cancer survivors were increased after HF (HR: 7.32; 95% CI: 2.56-20.89), CAD (HR: 5.54; 95% CI: 2.37-12.93), and stroke (HR: 3.57; 95% CI: 1.12-11.37). CAD-specific mortality risk was increased (HR: 3.70; 95% CI: 1.05-13.02). Among 5,114 CARDIA participants, 345 had a major event. Although CARDIA participants were on average decades older at events (median age 57 years vs 31 years), mortality risks were similar, except that all-cause mortality after CAD was significantly increased among childhood cancer survivors (HR: 1.85; 95% CI: 1.16-2.95).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Survivors of childhood cancer represent a population at high risk for mortality after major cardiovascular events.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38383098/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240222011100&v=2.18.0.post9+e462414">38383098</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.12.022>10.1016/j.jacc.2023.12.022</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38383098</guid>
<pubDate>Wed, 21 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Wendy Bottinor</dc:creator>
<dc:creator>Cindy Im</dc:creator>
<dc:creator>David R Doody</dc:creator>
<dc:creator>Saro H Armenian</dc:creator>
<dc:creator>Alexander Arynchyn</dc:creator>
<dc:creator>Borah Hong</dc:creator>
<dc:creator>Rebecca M Howell</dc:creator>
<dc:creator>David R Jacobs</dc:creator>
<dc:creator>Kirsten K Ness</dc:creator>
<dc:creator>Kevin C Oeffinger</dc:creator>
<dc:creator>Alexander P Reiner</dc:creator>
<dc:creator>Gregory T Armstrong</dc:creator>
<dc:creator>Yutaka Yasui</dc:creator>
<dc:creator>Eric J Chow</dc:creator>
<dc:date>2024-02-21</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Mortality After Major Cardiovascular Events in Survivors of Childhood Cancer</dc:title>
<dc:identifier>pmid:38383098</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.12.022</dc:identifier>
</item>
<item>
<title>Infective Endocarditis, Substance Use Disorder, and Relapse: There Is No Silver Bullet</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38383097/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240222011100&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Feb 27;83(8):824-826. doi: 10.1016/j.jacc.2023.12.017.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38383097/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240222011100&v=2.18.0.post9+e462414">38383097</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.12.017>10.1016/j.jacc.2023.12.017</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38383097</guid>
<pubDate>Wed, 21 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Krish C Dewan</dc:creator>
<dc:creator>Carmelo A Milano</dc:creator>
<dc:date>2024-02-21</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Infective Endocarditis, Substance Use Disorder, and Relapse: There Is No Silver Bullet</dc:title>
<dc:identifier>pmid:38383097</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.12.017</dc:identifier>
</item>
<item>
<title>Infective Endocarditis in Patients Addicted to Injected Opioid Drugs</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38383096/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240222011100&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Infective endocarditis surgery can be performed with low mortality in persons who inject drugs, but addiction is far more lethal. Risk of loss to follow-up and relapse require more effective addiction strategies without which this major loss to society will continue.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Feb 27;83(8):811-823. doi: 10.1016/j.jacc.2023.12.016.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Persons who inject drugs and require surgery for infective endocarditis have 2 potentially lethal diseases. Current postoperative rehabilitation efforts seem ineffective in preventing loss to follow-up, injection drug use relapse (relapse), and death.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The purpose of this study was to characterize drug use, psychosocial issues, surgical outcome, and postoperative addiction management, as well as loss to follow-up, relapse, and mortality and their risk factors.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: From January 2010 to June 2020, 227 persons who inject drugs, age 36 ± 9.9 years, underwent surgery for infective endocarditis at a quaternary hospital having special interest in developing addiction management programs. Postsurgery loss to follow-up, relapse, and death were assessed as competing risks and risk factors identified parametrically and by machine learning. CIs are 68% (±1 SE).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Heroin was the most self-reported drug injected (n = 183 [81%]). Psychosocial issues included homelessness (n = 56 [25%]), justice system involvement (n = 150 [66%]), depression (n = 118 [52%]), anxiety (n = 104 [46%]), and post-traumatic stress disorder (n = 33 [15%]). Four (1.8%) died in-hospital. Medication for opioid use disorder prescribed at discharge increased from 0% in 2010 to 100% in 2020. At 1 and 5 years, conditional probabilities of loss to follow-up were 16% (68% CI: 13%-22%) and 59% (68% CI: 44%-65%), relapse 32% (68% CI: 28%-34%) and 79% (68% CI: 74%-83%), and mortality 21% (68% CI: 18%-23%) and 68% (68% CI: 62%-72%). Younger age, heroin use, and lower education level were predictors of relapse.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Infective endocarditis surgery can be performed with low mortality in persons who inject drugs, but addiction is far more lethal. Risk of loss to follow-up and relapse require more effective addiction strategies without which this major loss to society will continue.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38383096/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240222011100&v=2.18.0.post9+e462414">38383096</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.12.016>10.1016/j.jacc.2023.12.016</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38383096</guid>
<pubDate>Wed, 21 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Michael J Javorski</dc:creator>
<dc:creator>Brad F Rosinski</dc:creator>
<dc:creator>Shawn Shah</dc:creator>
<dc:creator>Matthew A Thompson</dc:creator>
<dc:creator>David Streem</dc:creator>
<dc:creator>Steven M Gordon</dc:creator>
<dc:creator>Steven Insler</dc:creator>
<dc:creator>Penny L Houghtaling</dc:creator>
<dc:creator>Brian Griffin</dc:creator>
<dc:creator>Eugene H Blackstone</dc:creator>
<dc:creator>Shinya Unai</dc:creator>
<dc:creator>Lars G Svensson</dc:creator>
<dc:creator>Gösta B Pettersson</dc:creator>
<dc:creator>Haytham Elgharably</dc:creator>
<dc:date>2024-02-21</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Infective Endocarditis in Patients Addicted to Injected Opioid Drugs</dc:title>
<dc:identifier>pmid:38383096</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.12.016</dc:identifier>
</item>
<item>
<title>Precision Phenotyping in Arrhythmogenic Cardiomyopathy: What's in a Name?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38383095/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240222011100&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Feb 27;83(8):808-810. doi: 10.1016/j.jacc.2024.01.007.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38383095/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240222011100&v=2.18.0.post9+e462414">38383095</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.01.007>10.1016/j.jacc.2024.01.007</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38383095</guid>
<pubDate>Wed, 21 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Amy R Kontorovich</dc:creator>
<dc:date>2024-02-21</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Precision Phenotyping in Arrhythmogenic Cardiomyopathy: What's in a Name?</dc:title>
<dc:identifier>pmid:38383095</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.01.007</dc:identifier>
</item>
<item>
<title>Phenotypic Expression and Clinical Outcomes in Patients With Arrhythmogenic Cardiomyopathies</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38383094/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240222011100&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: The comparison of ACM phenotypes demonstrated that patients with right ventricular involvement, such as ARVC and BIV forms, exhibit a higher incidence of life-threatening ventricular arrhythmias. Conversely, ACM forms characterized by left ventricular involvement, such as ALVC and BIV, show a higher incidence of heart failure, heart transplantation, and hot phases.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Feb 27;83(8):797-807. doi: 10.1016/j.jacc.2023.12.015.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: In recent years, it has become evident that arrhythmogenic cardiomyopathy (ACM) displays a wide spectrum of ventricular involvement. Furthermore, the influence of various clinical phenotypes on the prognosis of the disease is currently being assessed.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The purpose of this study was to evaluate the impact of phenotypic expression in ACM on patient outcomes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We conducted an analysis of 446 patients diagnosed with ACM. These patients were categorized into 3 groups based on their phenotype: arrhythmogenic right ventricular cardiomyopathy (ARVC) (right-dominant ACM), arrhythmogenic left ventricular cardiomyopathy (ALVC) (left-dominant ACM), and biventricular arrhythmogenic cardiomyopathy (BIV). We compared clinical, instrumental, and genetic findings among these groups and also evaluated their outcomes RESULTS: Overall, 44% of patients were diagnosed with ARVC, 23% with ALVC, and 33% with BIV forms. Subjects showing with ARVC and BIV phenotype had a significantly higher incidence of life-threatening ventricular arrhythmias compared with ALVC (P &lt; 0.001). On the other hand, heart failure, heart transplantation, and death caused by cardiac causes were more frequent in individuals with BIV forms compared to those with ALVC and ARVC (P &lt; 0.001). Finally, patients with an ALVC phenotype had a higher incidence of hot phases compared with those with ARVC and BIV forms (P = 0.013).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The comparison of ACM phenotypes demonstrated that patients with right ventricular involvement, such as ARVC and BIV forms, exhibit a higher incidence of life-threatening ventricular arrhythmias. Conversely, ACM forms characterized by left ventricular involvement, such as ALVC and BIV, show a higher incidence of heart failure, heart transplantation, and hot phases.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38383094/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240222011100&v=2.18.0.post9+e462414">38383094</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.12.015>10.1016/j.jacc.2023.12.015</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38383094</guid>
<pubDate>Wed, 21 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Riccardo Bariani</dc:creator>
<dc:creator>Ilaria Rigato</dc:creator>
<dc:creator>Rudy Celeghin</dc:creator>
<dc:creator>Maria Bueno Marinas</dc:creator>
<dc:creator>Alberto Cipriani</dc:creator>
<dc:creator>Alessandro Zorzi</dc:creator>
<dc:creator>Valeria Pergola</dc:creator>
<dc:creator>Sabino Iliceto</dc:creator>
<dc:creator>Cristina Basso</dc:creator>
<dc:creator>Martina Perazzolo Marra</dc:creator>
<dc:creator>Domenico Corrado</dc:creator>
<dc:creator>Dario Gregori</dc:creator>
<dc:creator>Kalliopi Pilichou</dc:creator>
<dc:creator>Barbara Bauce</dc:creator>
<dc:date>2024-02-21</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Phenotypic Expression and Clinical Outcomes in Patients With Arrhythmogenic Cardiomyopathies</dc:title>
<dc:identifier>pmid:38383094</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.12.015</dc:identifier>
</item>
<item>
<title>Sex-Specific Mortality Benefits Related to Exercise</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38383093/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240222011100&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Feb 27;83(8):794-796. doi: 10.1016/j.jacc.2024.01.003.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38383093/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240222011100&v=2.18.0.post9+e462414">38383093</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.01.003>10.1016/j.jacc.2024.01.003</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38383093</guid>
<pubDate>Wed, 21 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Wael A Jaber</dc:creator>
<dc:creator>Erika Hutt</dc:creator>
<dc:date>2024-02-21</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Sex-Specific Mortality Benefits Related to Exercise</dc:title>
<dc:identifier>pmid:38383093</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.01.003</dc:identifier>
</item>
<item>
<title>Sex Differences in Association of Physical Activity With All-Cause and Cardiovascular Mortality</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38383092/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240222011100&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Women compared with men derived greater gains in all-cause and cardiovascular mortality risk reduction from equivalent doses of leisure-time physical activity. These findings could enhance efforts to close the "gender gap" by motivating especially women to engage in any regular leisure-time physical activity.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Feb 27;83(8):783-793. doi: 10.1016/j.jacc.2023.12.019.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Although physical activity is widely recommended for reducing cardiovascular and all-cause mortality risks, female individuals consistently lag behind male individuals in exercise engagement.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The goal of this study was to evaluate whether physical activity derived health benefits may differ by sex.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: In a prospective study of 412,413 U.S. adults (55% female, age 44 ± 17 years) who provided survey data on leisure-time physical activity, we examined sex-specific multivariable-adjusted associations of physical activity measures (frequency, duration, intensity, type) with all-cause and cardiovascular mortality from 1997 through 2019.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: During 4,911,178 person-years of follow-up, there were 39,935 all-cause deaths including 11,670 cardiovascular deaths. Regular leisure-time physical activity compared with inactivity was associated with 24% (HR: 0.76; 95% CI: 0.73-0.80) and 15% (HR: 0.85; 95% CI: 0.82-0.89) lower risk of all-cause mortality in women and men, respectively (Wald F = 12.0, sex interaction P &lt; 0.001). Men reached their maximal survival benefit of HR 0.81 from 300 min/wk of moderate-to-vigorous physical activity, whereas women achieved similar benefit at 140 min/wk and then continued to reach a maximum survival benefit of HR 0.76 also at ∼300 min/wk. Sex-specific findings were similar for cardiovascular death (Wald F = 20.1, sex interaction P &lt; 0.001) and consistent across all measures of aerobic activity as well as muscle strengthening activity (Wald F = 6.7, sex interaction P = 0.009).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Women compared with men derived greater gains in all-cause and cardiovascular mortality risk reduction from equivalent doses of leisure-time physical activity. These findings could enhance efforts to close the "gender gap" by motivating especially women to engage in any regular leisure-time physical activity.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38383092/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240222011100&v=2.18.0.post9+e462414">38383092</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.12.019>10.1016/j.jacc.2023.12.019</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38383092</guid>
<pubDate>Wed, 21 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Hongwei Ji</dc:creator>
<dc:creator>Martha Gulati</dc:creator>
<dc:creator>Tzu Yu Huang</dc:creator>
<dc:creator>Alan C Kwan</dc:creator>
<dc:creator>David Ouyang</dc:creator>
<dc:creator>Joseph E Ebinger</dc:creator>
<dc:creator>Kaitlin Casaletto</dc:creator>
<dc:creator>Kerrie L Moreau</dc:creator>
<dc:creator>Hicham Skali</dc:creator>
<dc:creator>Susan Cheng</dc:creator>
<dc:date>2024-02-21</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Sex Differences in Association of Physical Activity With All-Cause and Cardiovascular Mortality</dc:title>
<dc:identifier>pmid:38383092</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.12.019</dc:identifier>
</item>
<item>
<title>Correction to: 2023 ESC Guidelines for the management of acute coronary syndromes: Developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC)</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38383069/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240222011100&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Feb 22:ehad870. doi: 10.1093/eurheartj/ehad870. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38383069/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240222011100&v=2.18.0.post9+e462414">38383069</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad870>10.1093/eurheartj/ehad870</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38383069</guid>
<pubDate>Wed, 21 Feb 2024 06:00:00 -0500</pubDate>
<dc:date>2024-02-21</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Correction to: 2023 ESC Guidelines for the management of acute coronary syndromes: Developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC)</dc:title>
<dc:identifier>pmid:38383069</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad870</dc:identifier>
</item>
<item>
<title>Mouse oocytes sequester aggregated proteins in degradative super-organelles</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38382525/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240222011100&amp;v=2.18.0.post9+e462414
      <description>Oocytes are among the longest-lived cells in the body and need to preserve their cytoplasm to support proper embryonic development. Protein aggregation is a major threat for intracellular homeostasis in long-lived cells. How oocytes cope with protein aggregation during their extended life is unknown. Here, we find that mouse oocytes accumulate protein aggregates in specialized compartments that we named endolysosomal vesicular assemblies (ELVAs). Combining live-cell imaging, electron microscopy,...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Feb 9:S0092-8674(24)00068-0. doi: 10.1016/j.cell.2024.01.031. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Oocytes are among the longest-lived cells in the body and need to preserve their cytoplasm to support proper embryonic development. Protein aggregation is a major threat for intracellular homeostasis in long-lived cells. How oocytes cope with protein aggregation during their extended life is unknown. Here, we find that mouse oocytes accumulate protein aggregates in specialized compartments that we named endolysosomal vesicular assemblies (ELVAs). Combining live-cell imaging, electron microscopy, and proteomics, we found that ELVAs are non-membrane-bound compartments composed of endolysosomes, autophagosomes, and proteasomes held together by a protein matrix formed by RUFY1. Functional assays revealed that in immature oocytes, ELVAs sequester aggregated proteins, including TDP-43, and degrade them upon oocyte maturation. Inhibiting degradative activity in ELVAs leads to the accumulation of protein aggregates in the embryo and is detrimental for embryo survival. Thus, ELVAs represent a strategy to safeguard protein homeostasis in long-lived cells.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38382525/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240222011100&v=2.18.0.post9+e462414">38382525</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.01.031>10.1016/j.cell.2024.01.031</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38382525</guid>
<pubDate>Wed, 21 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Gabriele Zaffagnini</dc:creator>
<dc:creator>Shiya Cheng</dc:creator>
<dc:creator>Marion C Salzer</dc:creator>
<dc:creator>Barbara Pernaute</dc:creator>
<dc:creator>Juan Manuel Duran</dc:creator>
<dc:creator>Manuel Irimia</dc:creator>
<dc:creator>Melina Schuh</dc:creator>
<dc:creator>Elvan Böke</dc:creator>
<dc:date>2024-02-21</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Mouse oocytes sequester aggregated proteins in degradative super-organelles</dc:title>
<dc:identifier>pmid:38382525</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.01.031</dc:identifier>
</item>
<item>
<title>Structural mechanisms of α7 nicotinic receptor allosteric modulation and activation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38382524/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240222011100&amp;v=2.18.0.post9+e462414
      <description>The α7 nicotinic acetylcholine receptor is a pentameric ligand-gated ion channel that plays an important role in cholinergic signaling throughout the nervous system. Its unique physiological characteristics and implications in neurological disorders and inflammation make it a promising but challenging therapeutic target. Positive allosteric modulators overcome limitations of traditional α7 agonists, but their potentiation mechanisms remain unclear. Here, we present high-resolution structures of...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Feb 13:S0092-8674(24)00099-0. doi: 10.1016/j.cell.2024.01.032. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The α7 nicotinic acetylcholine receptor is a pentameric ligand-gated ion channel that plays an important role in cholinergic signaling throughout the nervous system. Its unique physiological characteristics and implications in neurological disorders and inflammation make it a promising but challenging therapeutic target. Positive allosteric modulators overcome limitations of traditional α7 agonists, but their potentiation mechanisms remain unclear. Here, we present high-resolution structures of α7-modulator complexes, revealing partially overlapping binding sites but varying conformational states. Structure-guided functional and computational tests suggest that differences in modulator activity arise from the stable rotation of a channel gating residue out of the pore. We extend the study using a time-resolved cryoelectron microscopy (cryo-EM) approach to reveal asymmetric state transitions for this homomeric channel and also find that a modulator with allosteric agonist activity exploits a distinct channel-gating mechanism. These results define mechanisms of α7 allosteric modulation and activation with implications across the pentameric receptor superfamily.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38382524/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240222011100&v=2.18.0.post9+e462414">38382524</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.01.032>10.1016/j.cell.2024.01.032</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38382524</guid>
<pubDate>Wed, 21 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Sean M Burke</dc:creator>
<dc:creator>Mariia Avstrikova</dc:creator>
<dc:creator>Colleen M Noviello</dc:creator>
<dc:creator>Nuriya Mukhtasimova</dc:creator>
<dc:creator>Jean-Pierre Changeux</dc:creator>
<dc:creator>Ganesh A Thakur</dc:creator>
<dc:creator>Steven M Sine</dc:creator>
<dc:creator>Marco Cecchini</dc:creator>
<dc:creator>Ryan E Hibbs</dc:creator>
<dc:date>2024-02-21</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Structural mechanisms of α7 nicotinic receptor allosteric modulation and activation</dc:title>
<dc:identifier>pmid:38382524</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.01.032</dc:identifier>
</item>
<item>
<title>Innovative approaches to risk stratification in interventional cardiology</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38381944/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240222011100&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Feb 21;45(8):557-560. doi: 10.1093/eurheartj/ehae097.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38381944/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240222011100&v=2.18.0.post9+e462414">38381944</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae097>10.1093/eurheartj/ehae097</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38381944</guid>
<pubDate>Wed, 21 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2024-02-21</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Innovative approaches to risk stratification in interventional cardiology</dc:title>
<dc:identifier>pmid:38381944</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae097</dc:identifier>
</item>
<item>
<title>Interventions for Optimization of Guideline-Directed Medical Therapy: A Systematic Review</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38381449/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240222011100&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: This review summarizes interventions aimed at optimization of GDMT in clinical practice. Initiatives that used interdisciplinary teams, largely comprised of nurses and pharmacists, most consistently led to improvements in GDMT. Additional large, randomized studies are necessary to better understand other types of interventions, as well as their long-term efficacy and sustainability.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Feb 21. doi: 10.1001/jamacardio.2023.5627. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Implementation of guideline-directed medical therapy (GDMT) in real-world practice remains suboptimal. It is unclear which interventions are most effective at addressing current barriers to GDMT in patients with heart failure with reduced ejection fraction (HFrEF).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To perform a systematic review to identify which types of system-level initiatives are most effective at improving GDMT use among patients with HFrEF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EVIDENCE REVIEW: PubMed, Embase, Cochrane, CINAHL, and Web of Science databases were queried from January 2010 to November 2023 for randomized clinical trials that implemented a quality improvement intervention with GDMT use as a primary or secondary outcome. References from related review articles were also included for screening. Quality of studies and bias assessment were graded based on the Cochrane Risk of Bias tool and Oxford Centre for Evidence-Based Medicine.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">FINDINGS: Twenty-eight randomized clinical trials were included with an aggregate sample size of 19 840 patients. Studies were broadly categorized as interdisciplinary interventions (n = 15), clinician education (n = 5), electronic health record initiatives (n = 6), or patient education (n = 2). Overall, interdisciplinary titration clinics were associated with significant increases in the proportion of patients on target doses of GDMT with a 10% to 60% and 2% to 53% greater proportion of patients on target doses of β-blockers and renin-angiotensin-aldosterone system inhibitors, respectively, in intervention groups compared with usual care. Other interventions, such as audits, clinician and patient education, or electronic health record alerts, were also associated with some improvements in GDMT utilization, though these findings were inconsistent across studies.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: This review summarizes interventions aimed at optimization of GDMT in clinical practice. Initiatives that used interdisciplinary teams, largely comprised of nurses and pharmacists, most consistently led to improvements in GDMT. Additional large, randomized studies are necessary to better understand other types of interventions, as well as their long-term efficacy and sustainability.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38381449/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240222011100&v=2.18.0.post9+e462414">38381449</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.5627>10.1001/jamacardio.2023.5627</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38381449</guid>
<pubDate>Wed, 21 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Amber B Tang</dc:creator>
<dc:creator>Nicholas K Brownell</dc:creator>
<dc:creator>Jacob S Roberts</dc:creator>
<dc:creator>Amier Haidar</dc:creator>
<dc:creator>Antonia Osuna-Garcia</dc:creator>
<dc:creator>David J Cho</dc:creator>
<dc:creator>Pooya Bokhoor</dc:creator>
<dc:creator>Gregg C Fonarow</dc:creator>
<dc:date>2024-02-21</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Interventions for Optimization of Guideline-Directed Medical Therapy: A Systematic Review</dc:title>
<dc:identifier>pmid:38381449</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.5627</dc:identifier>
</item>
<item>
<title>Accelerometer-Measured Physical Activity, Sedentary Time, and Heart Failure Risk in Women Aged 63 to 99 Years</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38381446/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240222011100&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: Higher accelerometer-measured PA (MVPA, light PA, steps per day) was associated with lower risk (and greater total sedentary time with higher risk) of overall HF and HFpEF in a racially and ethnically diverse cohort of older women. Increasing PA and reducing sedentary time for primary HFpEF prevention may have relevant implications for cardiovascular resilience and healthy aging in later life.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Feb 21. doi: 10.1001/jamacardio.2023.5692. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Heart failure (HF) prevention is paramount to public health in the 21st century.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To examine incident HF and its subtypes with preserved ejection fraction (HFpEF) and reduced EF (HFrEF) according to accelerometer-measured physical activity (PA) and sedentary time.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This was a prospective cohort study, the Objective Physical Activity and Cardiovascular Health (OPACH) in Older Women study, conducted from March 2012 to April 2014. Included in the analysis were women aged 63 to 99 years without known HF, who completed hip-worn triaxial accelerometry for 7 consecutive days. Follow-up for incident HF occurred through February 2022. Data were analyzed from March to December 2023.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURE: Daily PA (total, light, moderate to vigorous PA [MVPA], steps) and sedentary (total, mean bout duration) behavior.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Adjudicated incident HF, HFpEF, and HFrEF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 5951 women (mean [SD] age, 78.6 [6.8] years) without known HF were included in this analysis. Women self-identified with the following race and ethnicity categories: 2004 non-Hispanic Black (33.7%), 1022 Hispanic (17.2%), and 2925 non-Hispanic White (49.2%). There were 407 HF cases (257 HFpEF; 110 HFrEF) identified through a mean (SD) of 7.5 (2.6) years (range, 0.01-9.9 years) of follow-up. Fully adjusted hazard ratios (HRs) for overall HF, HFpEF, and HFrEF associated with a 1-SD increment were 0.85 (95% CI, 0.75-0.95), 0.78 (95% CI, 0.67-0.91), and 1.02 (95% CI, 0.81-1.28) for minutes per day total PA; 0.74 (95% CI, 0.63-0.88), 0.71 (95% CI, 0.57-0.88), and 0.83 (95% CI, 0.62-1.12) for steps per day; and 1.17 (95% CI, 1.04-1.33), 1.29 (95% CI, 1.10-1.51), and 0.94 (95% CI, 0.75-1.18) for minutes per day total sedentary. Cubic spline curves for overall HF and HFpEF were significant inverse for total PA and steps per day and positive for total sedentary. Light PA and MVPA were inversely associated with overall HF (HR per 1 SD: 0.88; 95% CI, 0.78-0.98 and 0.84; 95% CI, 0.73-0.97) and HFpEF (0.80; 95% CI, 0.70-0.93 and 0.85; 95% CI, 0.72-1.01) but not HFrEF. Associations did not meaningfully differ when stratified by age, race and ethnicity, body mass index, physical function, or comorbidity score. Results for sedentary bout duration were inconsistent.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Higher accelerometer-measured PA (MVPA, light PA, steps per day) was associated with lower risk (and greater total sedentary time with higher risk) of overall HF and HFpEF in a racially and ethnically diverse cohort of older women. Increasing PA and reducing sedentary time for primary HFpEF prevention may have relevant implications for cardiovascular resilience and healthy aging in later life.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38381446/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240222011100&v=2.18.0.post9+e462414">38381446</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.5692>10.1001/jamacardio.2023.5692</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38381446</guid>
<pubDate>Wed, 21 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Michael J LaMonte</dc:creator>
<dc:creator>Andrea Z LaCroix</dc:creator>
<dc:creator>Steve Nguyen</dc:creator>
<dc:creator>Kelly R Evenson</dc:creator>
<dc:creator>Chongzhi Di</dc:creator>
<dc:creator>Marcia L Stefanick</dc:creator>
<dc:creator>Eric T Hyde</dc:creator>
<dc:creator>Blake Anuskiewicz</dc:creator>
<dc:creator>Charles B Eaton</dc:creator>
<dc:date>2024-02-21</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Accelerometer-Measured Physical Activity, Sedentary Time, and Heart Failure Risk in Women Aged 63 to 99 Years</dc:title>
<dc:identifier>pmid:38381446</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.5692</dc:identifier>
</item>
<item>
<title>Statins, Inflammation, and Tissue Context in REPRIEVE</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38381416/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240222011100&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Feb 21. doi: 10.1001/jamacardio.2023.5671. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38381416/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240222011100&v=2.18.0.post9+e462414">38381416</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.5671>10.1001/jamacardio.2023.5671</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38381416</guid>
<pubDate>Wed, 21 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Matthew J Feinstein</dc:creator>
<dc:date>2024-02-21</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Statins, Inflammation, and Tissue Context in REPRIEVE</dc:title>
<dc:identifier>pmid:38381416</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.5671</dc:identifier>
</item>
<item>
<title>Effects of Pitavastatin on Coronary Artery Disease and Inflammatory Biomarkers in HIV: Mechanistic Substudy of the REPRIEVE Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38381407/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240222011100&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: In PWH at low to moderate CVD risk, 24 months of pitavastatin reduced noncalcified plaque volume and progression as well as markers of lipid oxidation and arterial inflammation. These changes may contribute to the observed MACE reduction in REPRIEVE.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Feb 21. doi: 10.1001/jamacardio.2023.5661. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Cardiovascular disease (CVD) is increased in people with HIV (PWH) and is characterized by premature noncalcified coronary plaque. In the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE), pitavastatin reduced major adverse cardiovascular events (MACE) by 35% over a median of 5.1 years.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To investigate the effects of pitavastatin on noncalcified coronary artery plaque by coronary computed tomography angiography (CTA) and on inflammatory biomarkers as potential mechanisms for MACE prevention.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This double-blind, placebo-controlled randomized clinical trial enrolled participants from April 2015 to February 2018 at 31 US clinical research sites. PWH without known CVD who were taking antiretroviral therapy and had low to moderate 10-year CVD risk were included. Data were analyzed from April to November 2023.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTION: Oral pitavastatin calcium, 4 mg per day.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Coronary CTA and inflammatory biomarkers at baseline and 24 months. The primary outcomes were change in noncalcified coronary plaque volume and progression of noncalcified plaque.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 804 enrolled persons, 774 had at least 1 evaluable CTA. Plaque changes were assessed in 611 who completed both CT scans. Of 611 analyzed participants, 513 (84.0%) were male, the mean (SD) age was 51 (6) years, and the median (IQR) 10-year CVD risk was 4.5% (2.6-7.0). A total of 302 were included in the pitavastatin arm and 309 in the placebo arm. The mean noncalcified plaque volume decreased with pitavastatin compared with placebo (mean [SD] change, -1.7 [25.2] mm3 vs 2.6 [27.1] mm3; baseline adjusted difference, -4.3 mm3; 95% CI, -8.6 to -0.1; P = .04; 7% [95% CI, 1-12] greater reduction relative to placebo). A larger effect size was seen among the subgroup with plaque at baseline (-8.8 mm3 [95% CI, -17.9 to 0.4]). Progression of noncalcified plaque was 33% less likely with pitavastatin compared with placebo (relative risk, 0.67; 95% CI, 0.52-0.88; P = .003). Compared with placebo, the mean low-density lipoprotein cholesterol decreased with pitavastatin (mean change: pitavastatin, -28.5 mg/dL; 95% CI, -31.9 to -25.1; placebo, -0.8; 95% CI, -3.8 to 2.2). The pitavastatin arm had a reduction in both oxidized low-density lipoprotein (-29% [95% CI, -32 to -26] vs -13% [95% CI, -17 to -9]; P &lt; .001) and lipoprotein-associated phospholipase A2 (-7% [95% CI, -11 to -4] vs 14% [95% CI, 10-18]; P &lt; .001) compared with placebo at 24 months.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In PWH at low to moderate CVD risk, 24 months of pitavastatin reduced noncalcified plaque volume and progression as well as markers of lipid oxidation and arterial inflammation. These changes may contribute to the observed MACE reduction in REPRIEVE.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02344290.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38381407/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240222011100&v=2.18.0.post9+e462414">38381407</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.5661>10.1001/jamacardio.2023.5661</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38381407</guid>
<pubDate>Wed, 21 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Michael T Lu</dc:creator>
<dc:creator>Heather Ribaudo</dc:creator>
<dc:creator>Borek Foldyna</dc:creator>
<dc:creator>Markella V Zanni</dc:creator>
<dc:creator>Thomas Mayrhofer</dc:creator>
<dc:creator>Julia Karady</dc:creator>
<dc:creator>Jana Taron</dc:creator>
<dc:creator>Kathleen V Fitch</dc:creator>
<dc:creator>Sara McCallum</dc:creator>
<dc:creator>Tricia H Burdo</dc:creator>
<dc:creator>Kayla Paradis</dc:creator>
<dc:creator>Sandeep S Hedgire</dc:creator>
<dc:creator>Nandini M Meyersohn</dc:creator>
<dc:creator>Christopher DeFilippi</dc:creator>
<dc:creator>Carlos D Malvestutto</dc:creator>
<dc:creator>Audra Sturniolo</dc:creator>
<dc:creator>Marissa Diggs</dc:creator>
<dc:creator>Sue Siminski</dc:creator>
<dc:creator>Gerald S Bloomfield</dc:creator>
<dc:creator>Beverly Alston-Smith</dc:creator>
<dc:creator>Patrice Desvigne-Nickens</dc:creator>
<dc:creator>Edgar T Overton</dc:creator>
<dc:creator>Judith S Currier</dc:creator>
<dc:creator>Judith A Aberg</dc:creator>
<dc:creator>Carl J Fichtenbaum</dc:creator>
<dc:creator>Udo Hoffmann</dc:creator>
<dc:creator>Pamela S Douglas</dc:creator>
<dc:creator>Steven K Grinspoon</dc:creator>
<dc:creator>REPRIEVE Trial Writing Group</dc:creator>
<dc:date>2024-02-21</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Effects of Pitavastatin on Coronary Artery Disease and Inflammatory Biomarkers in HIV: Mechanistic Substudy of the REPRIEVE Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:38381407</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.5661</dc:identifier>
</item>
<item>
<title>The year in cardiovascular medicine 2023: the top 10 papers in valvular heart disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38380439/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240222011100&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Feb 21:ehae090. doi: 10.1093/eurheartj/ehae090. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38380439/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240222011100&v=2.18.0.post9+e462414">38380439</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae090>10.1093/eurheartj/ehae090</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38380439</guid>
<pubDate>Wed, 21 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>David Messika-Zeitoun</dc:creator>
<dc:creator>Bernard Iung</dc:creator>
<dc:creator>Helmut Baumgartner</dc:creator>
<dc:date>2024-02-21</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The year in cardiovascular medicine 2023: the top 10 papers in valvular heart disease</dc:title>
<dc:identifier>pmid:38380439</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae090</dc:identifier>
</item>
<item>
<title>Surgical or percutaneous treatment of mitral regurgitation: clip or cut?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38379446/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240222011100&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Feb 21:ehae084. doi: 10.1093/eurheartj/ehae084. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38379446/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240222011100&v=2.18.0.post9+e462414">38379446</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae084>10.1093/eurheartj/ehae084</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38379446</guid>
<pubDate>Wed, 21 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Philipp Lurz</dc:creator>
<dc:creator>Karl-Patrik Kresoja</dc:creator>
<dc:date>2024-02-21</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Surgical or percutaneous treatment of mitral regurgitation: clip or cut?</dc:title>
<dc:identifier>pmid:38379446</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae084</dc:identifier>
</item>





























</channel>
</rss>